Viking says VK2735 holds 97% of weight loss on every-other-week dosing
Shares rose 40% premarket after the company reported maintenance data over 12 weeks following an initial 21-week treatment period.
TR
By Tom Reyes · Markets Editor
Sep 22 08:14 ETSource: Emirates 24|7
The wire
- 01Viking Therapeutics said patients switched to every-other-week VK2735 maintained up to 97% of weight lost during 21 weeks of treatment, while monthly dosing retained up to 90% over 12 weeks.
- 02Less frequent maintenance dosing could reduce treatment burden and cost of therapy, a differentiator against Novo Nordisk and Eli Lilly incretins.
- 03A small subgroup staying on weekly dosing for 33 weeks lost 21.7% of body weight; oral maintenance dosing is planned in a future part of the trial.
From the source
Read at emirates247.comViking Therapeutics' obesity drug shows durable weight-loss benefit, shares jump
VK2735 obesity drug maintained up to 97% of prior weight loss with less frequent dosing, lifting shares 40% as it advances injectable and oral options for a market projected to hit $100B by 2030